» Articles » PMID: 29310638

The Use of an Alternate Side Lying Positioning Strategy During Inhalation Therapy Does Not Prolong Nebulisation Time in Adults with Cystic Fibrosis: a Randomised Crossover Trial

Overview
Journal BMC Pulm Med
Publisher Biomed Central
Specialty Pulmonary Medicine
Date 2018 Jan 10
PMID 29310638
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Inhalation of nebulised medications is performed in upright sitting to maximise lung volumes. The pattern of deposition is poor for inhaled medications in people with Cystic Fibrosis. The pattern tends to be non-uniform and typically the upper lobes receive a reduced dose compared to the rest of the lung. One strategy that has been proposed as having the potential to improve homogeneity of deposition is to adopt an alternate side lying position for the inhalation procedure. This study sought to determine whether, among adults with Cystic Fibrosis, there is any disadvantage to delivery time of nebulised medications with a strategy of alternate side lying, compared to upright sitting.

Methods: A randomised crossover trial with concealed allocation, intention-to-treat analysis and blinded assessors was undertaken. The participants were 24 adults with stable Cystic Fibrosis. They inhaled 4 mL of normal saline via an LC Star™ nebuliser twice within 24 h. In random order, participants sat upright throughout nebulisation, or alternated between left and right side lying at each minute during the nebulisation period. The nebuliser was stopped and weighed each minute until the residual volume was reached. The primary outcome was the time required for 3.5 mL to be delivered. The secondary outcomes were: respiratory rate; ratio of the volume delivered on right and left sides; and calculation of how long the periods in side lying can be extended without causing greater than 20% discrepancy in dose delivered in the two positions.

Results: The delivery time did not significantly differ between sitting and side lying (mean difference 0.58 min, 95% confidence interval (CI) -1.40 to 0.24). There was no significant correlation between delivery time, lung function or subject height (all R < 0.4). Increasing side lying duration from 1 to 2 min did not significantly impact the dose delivered on each side. Turning each 3 min however, significantly worsened the disparity (mean ratio 1.32, 95% CI 1.24 to 1.40).

Conclusion: Side lying during inhalation therapy does not prolong nebulisation time. 2-min periods should provide an equal dose in the two side lying positions.

Trial Registration: Prospectively registered on 4 July 2011; ACTRN12611000672954 .

Citing Articles

Nebuliser systems for drug delivery in cystic fibrosis.

Stanford G, Morrison L, Brown C Cochrane Database Syst Rev. 2023; 11:CD007639.

PMID: 37942828 PMC: 10633867. DOI: 10.1002/14651858.CD007639.pub3.


Role of rehabilitation amidst the COVID-19 pandemic: a review.

Yu C, Johann Helwig E J Transl Med. 2021; 19(1):376.

PMID: 34481486 PMC: 8417619. DOI: 10.1186/s12967-021-03048-1.


Physical Medicine and Rehabilitation and Pulmonary Rehabilitation for COVID-19.

Wang T, Chau B, Lui M, Lam G, Lin N, Humbert S Am J Phys Med Rehabil. 2020; 99(9):769-774.

PMID: 32541352 PMC: 7315835. DOI: 10.1097/PHM.0000000000001505.


Side lying during nebulisation can significantly improve apical deposition in healthy adults and adults with mild cystic fibrosis lung disease: a randomised crossover trial.

Dentice R, Elkins M, Verschuer J, Eberl S, Dwyer G, Bye P BMC Pulm Med. 2019; 19(1):128.

PMID: 31311524 PMC: 6636004. DOI: 10.1186/s12890-019-0886-7.

References
1.
Laube B, Jashnani R, Dalby R, Zeitlin P . Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate. Chest. 2000; 118(4):1069-76. DOI: 10.1378/chest.118.4.1069. View

2.
Baskin M, Abd A, Ilowite J . Regional deposition of aerosolized pentamidine. Effects of body position and breathing pattern. Ann Intern Med. 1990; 113(9):677-83. DOI: 10.7326/0003-4819-113-9-677. View

3.
Ballmann M, von der Hardt H . Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. J Cyst Fibros. 2004; 1(1):35-7. DOI: 10.1016/s1569-1993(01)00009-1. View

4.
Ilowite J, Baskin M, Sheetz M, Abd A . Delivered dose and regional distribution of aerosolized pentamidine using different delivery systems. Chest. 1991; 99(5):1139-44. DOI: 10.1378/chest.99.5.1139. View

5.
Winslow E . Cardiovascular consequences of bed rest. Heart Lung. 1985; 14(3):236-46. View